Key points are not available for this paper at this time.
This JAMA Insights Clinical Update discusses management options for women with vulvovaginal atrophy, focusing on the systemic safety of estrogen-based therapies and shared decision-making based on preference, cost, and adverse effect profile.
Carolyn Crandall (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: